DaVita Inc. (NYSE:DVA) Receives Consensus Rating of “Moderate Buy” from Brokerages

DaVita Inc. (NYSE:DVA) has received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $233.4286.

A number of equities research analysts have recently issued reports on the company. Oppenheimer set a $220.00 target price on DaVita in a research report on Friday, August 7th. Truist Financial decreased their price target on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. UBS Group lifted their price target on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th.

DaVita Price Performance

DVA stock traded up $0.17 on Friday, reaching $183.26. The company’s stock had a trading volume of 97,851 shares, compared to its average volume of 917,797. DaVita has a 52 week low of $101.00 and a 52 week high of $247.49. The company has a market capitalization of $11.69 billion, a P/E ratio of 14.99, a price-to-earnings-growth ratio of 0.50 and a beta of 0.83. The firm has a fifty day moving average of $200.58 and a two-hundred day moving average of $186.72.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. During the same period last year, the firm posted $2.95 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts expect that DaVita will post 14.57 EPS for the current fiscal year.

Hedge Funds Weigh In On DaVita

Several institutional investors and hedge funds have recently modified their holdings of the stock. Root Financial Partners LLC increased its position in DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after purchasing an additional 105 shares during the last quarter. Sankala Group LLC acquired a new stake in shares of DaVita during the 4th quarter valued at about $39,000. Fideuram Asset Management Ireland dac bought a new stake in shares of DaVita in the 4th quarter valued at approximately $49,000. Western Wealth Management LLC acquired a new position in DaVita in the first quarter worth approximately $60,000. Finally, Canada Post Corp Registered Pension Plan increased its holdings in DaVita by 51.6% in the fourth quarter. Canada Post Corp Registered Pension Plan now owns 558 shares of the company’s stock worth $63,000 after buying an additional 190 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.